SI5 Global SI5 Global
✓ Produto localizado
Medicamentos E Saúde

INVEGA SUSTENNA 50 MG ML SERINGA PREENCHIDA 0 5 ML SIMILAR

Invega
GTIN / EAN
7896212424092
CEST
Não informado
Conteúdo
Não informado

Dados de produto preservados no idioma original.

INVEGA SUSTENNA 50 MG ML SERINGA PREENCHIDA 0 5 ML SIMILAR é fabricado pela Invega, na categoria Medicamentos E Saúde, com código de barras 7896212424092. Classificado no NCM 30049099 (Medicamentos (exceto os produtos das posições 30.02, 30.05 ou 30.06) constituídos por produtos misturados ou não misturados, preparados para fins terapêuticos ou profiláticos, apresentados em doses (incluindo os destinados a serem administrados por via percutânea) ou acondicionados para venda a retalho › Outros).

Fonte: SI5 Global · código registrado em Brasil · atualizado em 03/10/2026

WhatsApp

Preço base (referência): R$ 1.549,99 — coletado em paguemenos.com.br em 03/10/2026, pode não estar atualizado

Código de barras

7896212424092

Código registrado em Brasil · prefixo 789

Classificação fiscal

NCM
30049099Medicamentos (exceto os produtos das posições 30.02, 30.05 ou 30.06) constituídos por produtos misturados ou não misturados, preparados para fins terapêuticos ou profiláticos, apresentados em doses (incluindo os destinados a serem administrados por via percutânea) ou acondicionados para venda a retalho › Outros
Cadastro fiscal pronto para o seu ERP

NCM, CEST, CST/CSOSN, PIS/COFINS e cClassTrib do IBS/CBS deste produto para o seu regime. Até 50 produtos por dia, grátis.

Gerar cadastro fiscal

Descrição do produto

O que é Invega Sustenna 50mg Suspensão Injetável com 1 Seringa?

Invega Sustenna 50mg é uma suspensão injetável de liberação prolongada indicada para o tratamento da esquizofrenia e prevenção da recorrência dos sintomas. O medicamento contém palmitato de paliperidona, que age como antipsicótico, equilibrando os níveis de dopamina e serotonina no cérebro. Invega também é indicado no tratamento do transtorno esquizoafetivo, podendo ser usado sozinho ou em combinação com outros medicamentos.

Conteúdo da embalagem: 1 seringa preenchida com 0,5 mL contendo 50mg de paliperidona.

Fabricado por: Janssen

Composição Invega Sustenna 50mg:

Princípio ativo: 78mg de palmitato de paliperidona, equivalente a 50mg de palliperidona

Excipientes: Polissorbato 20, macrogol, ácido cítrico monoidratado, fosfato de sódio dibásico, fosfato de sódio monobásico, hidróxido de sódio, água para injetáveis.

Para que serve Invega Sustenna 50mg?

Invega Sustenna 50mg é indicado para:

  • Tratamento da esquizofrenia.
  • Prevenção da recorrência dos sintomas da esquizofrenia.
  • Tratamento do transtorno esquizoafetivo, em monoterapia ou como adjuvante a estabilizadores de humor ou antidepressivos.

Como devo usar Invega Sustenna 50mg?

O Invega Sustenna 50mg deve ser utilizado como dose de manutenção mensal após as doses iniciais recomendadas (150mg no primeiro dia e 100mg uma semana depois, ambas no músculo deltoide).

As doses mensais podem ser administradas no músculo deltoide ou glúteo, respeitando a dosagem indicada pelo médico, que pode variar entre 50 e 150 mg dependendo da tolerabilidade e eficácia individual.

Como funciona Invega Sustenna 50mg?

Invega Sustenna 50mg bloqueia os receptores de dopamina D2 e serotonina 5HT2A, ajudando a controlar os sintomas de esquizofrenia. A liberação prolongada proporciona controle contínuo dos sintomas.

Efeitos colaterais Invega Sustenna:

  • Tontura.
  • Aumento de peso.
  • Insônia.
  • Dor de cabeça.
  • Taquicardia.
  • Reações no local da injeção.
  • Movimentos involuntários (discinesia).

Cuidados importantes:

  • Invega Sustenna deve ser armazenado entre 15°C e 30°C, protegido da luz.
  • Não administrar por via intravenosa ou subcutânea.
  • Pode causar tontura, afetando a capacidade de operar máquinas ou dirigir.

Contraindicações:

  • Hipersensibilidade ao palmitato de paliperidona ou a qualquer componente da fórmula.
  • Contraindicado para pacientes com histórico de reação alérgica à risperidona.
  • Pacientes com distúrbios cardíacos, como síndrome do QT longo, devem utilizar com cautela.

Ficha técnica

Medicamento
True
MarcaPropria
Não
NumeroRegistroMS
1.1236.3398.004-9
NomeSubstanciaPrincipioAtivo
Paliperidoma
DescricaoBula
%0A%09%09%09%09%09%09%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3Ejanssen%3C%2Fp%3E%0A%3Ch2%3E%20Apresenta%26%23xE7%3B%26%23xE3%3Bo%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EComprimidos%20revestidos%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20de%203%2C%206%20e%209%20mg%20em%20embalagens%20%20com%207%20e%2028%20comprimidos.%3C%2Fp%3E%0A%3Ch2%3E%20INVEGA%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20indicado%20para%20o%20tratamento%20da%20esquizofrenia%2C%20incluindo%20tratamento%20agudo%20e%20preven%26%23xE7%3B%26%23xE3%3Bo%20de%20recorr%26%23xEA%3Bncia.%3C%2Fp%3E%0A%3Ch2%3E%20Contra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20hipersensibilidade%20conhecida%20%26%23xE0%3B%20paliperidona%20ou%20a%20qualquer%20componente%20da%20formula%26%23xE7%3B%26%23xE3%3Bo.%20Invega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20conhecida%20hipersensibilidade%20%26%23xE0%3B%20risperidona%2C%20uma%20vez%20que%20a%20paliperidona%20corresponde%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3ES%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20%20A%20ocorr%26%23xEA%3Bncia%20de%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20caracterizada%20%20por%20hipertermia%2C%20rigidez%20muscular%2C%20instabilidade%20auton%26%23xF4%3Bmica%2C%20%20altera%26%23xE7%3B%26%23xE3%3Bo%20da%20consci%26%23xEA%3Bncia%20e%20n%26%23xED%3Bveis%20elevados%20de%20creatina%20fosfoquinase%20%20t%26%23xEA%3Bm%20sido%20relatada%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20%20incluindo%20a%20paliperidona.%20Sinais%20cl%26%23xED%3Bnicos%20adicionais%20podem%20incluir%20%20mioglobin%26%23xFA%3Bria%20(rabdomi%26%23xF3%3Blise)%20e%20insufi%20ci%26%23xEA%3Bncia%20renal%20aguda.%20%20Se%20o%20paciente%20desenvolver%20sinais%20ou%20sintomas%20indicativos%20de%20%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20todos%20os%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20%20Invega%2C%20devem%20ser%20descontinuados.%20%20Discinesia%20tardia%20%20F%26%23xE1%3Brmacos%20com%20propriedades%20antagonistas%20de%20receptor%20dopamin%26%23xE9%3Brgico%20%20t%26%23xEA%3Bm%20sido%20associados%20%26%23xE0%3B%20indu%26%23xE7%3B%26%23xE3%3Bo%20de%20discinesia%20tardia%20%20caracterizada%20por%20movimentos%20involunt%26%23xE1%3Brios%2C%20r%26%23xED%3Btmicos%2C%20predominantemente%20%20da%20l%26%23xED%3Bngua%20e%2Fou%20da%20face.%20Se%20surgirem%20sinais%20ou%20%20sintomas%20de%20discinesia%20tardia%2C%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20de%20todos%20os%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%2C%20deve%20ser%20considerada.%20%20Intervalo%20QT%20%20Assim%20como%20outros%20antipsic%26%23xF3%3Bticos%2C%20deve-se%20ter%20cautela%20quando%20%20Invega%26%23x99%3B%20%26%23xE9%3B%20prescrito%20a%20pacientes%20com%20hist%26%23xF3%3Brico%20de%20arritmias%20%20card%26%23xED%3Bacas%2C%20em%20pacientes%20com%20s%26%23xED%3Bndrome%20cong%26%23xEA%3Bnita%20do%20prolongamento%20%20do%20intervalo%20QT%20e%20em%20uso%20concomitante%20com%20medicamentos%20%20que%20conhecidamente%20prolongam%20o%20intervalo%20QT.%20%20Hiperglicemia%20%20Casos%20raros%20de%20eventos%20adversos%20relacionados%20%26%23xE0%3B%20glicose%20%20foram%20relatados%20em%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%26%23x99%3B%20.%20Recomenda-%20%20se%20o%20monitoramento%20cl%26%23xED%3Bnico%20apropriado%20em%20pacientes%20%20diab%26%23xE9%3Bticos%20e%20em%20pacientes%20com%20fatores%20de%20risco%20para%20o%20desenvolvimento%20%20de%20diabetes%20mellitus.%20%20Hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20%20A%20paliperidona%20pode%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20em%20alguns%20%20pacientes%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20de%20sua%20atividade%20de%20bloqueador%20alfa.%20Invega%20%20%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20%20de%20doen%26%23xE7%3Ba%20cardiovascular%20(como%20por%20exemplo%2C%20insufi%20ci%26%23xEA%3Bncia%20%20card%26%23xED%3Baca%2C%20infarto%20ou%20isquemia%20do%20mioc%26%23xE1%3Brdio%2C%20anormalidades%20da%20condu%26%23xE7%3B%26%23xE3%3Bo)%2C%20doen%26%23xE7%3Ba%20vascular%20cerebral%20ou%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20%20predisponham%20o%20paciente%20%26%23xE0%3B%20hipotens%26%23xE3%3Bo%20(como%20por%20exemplo%2C%20%20desidrata%26%23xE7%3B%26%23xE3%3Bo%2C%20hipovolemia%20e%20tratamento%20com%20medicamentos%20%20anti-hipertensivos).%20%20Crises%20epil%26%23xE9%3Bpticas%20%20Da%20mesma%20forma%20que%20outros%20antipsic%26%23xF3%3Bticos%2C%20Invega%26%23x99%3B%20deve%20%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20crises%20%20epil%26%23xE9%3Bpticas%20ou%20outras%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20reduzem%20potencialmente%20%20o%20limiar%20convulsivo.%20%20Potencial%20para%20obstru%26%23xE7%3B%26%23xE3%3Bo%20gastrintestinal%20%20Uma%20vez%20que%20o%20comprimido%20de%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20se%20deforma%20e%20n%26%23xE3%3Bo%20%20altera%20sua%20forma%20no%20trato%20gastrintestinal%2C%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20deve%20%20ser%20administrado%20a%20pacientes%20com%20estreitamento%20gastrintestinal%20%20grave%20preexistente%20(patol%26%23xF3%3Bgico%20ou%20iatrog%26%23xEA%3Bnico)%20ou%20em%20pacientes%20%20com%20disfagia%20ou%20difi%20culdade%20signifi%20cante%20para%20deglutir%20comprimidos.%20%20Tem%20havido%20relatos%20raros%20de%20sintomas%20de%20obstru%26%23xE7%3B%26%23xE3%3Bo%20em%20%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20estreitamento%20associado%20%26%23xE0%3B%20ingest%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20em%20formula%26%23xE7%3B%26%23xF5%3Bes%20n%26%23xE3%3Bo%20deform%26%23xE1%3Bveis%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20%20controlada.%20Devido%20ao%20desenho%20da%20forma%20farmac%26%23xEA%3Butica%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%2C%20Invega%26%23x99%3B%20s%26%23xF3%3B%20deve%20ser%20usado%20em%20pacientes%20%20capazes%20de%20deglutir%20o%20comprimido%20inteiro.%20%20Pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20foi%20estudado%20nessa%20popula%26%23xE7%3B%26%23xE3%3Bo%20de%20pacientes%2C%20%20desta%20forma%20o%20medicamento%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendado%20para%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia.%20%20Mortalidade%20geral%20%20Em%20uma%20meta-an%26%23xE1%3Blise%20de%2017%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20%20pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20tratados%20com%20outros%20f%26%23xE1%3Brmacos%20%20antipsic%26%23xF3%3Bticos%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%2C%20%20olanzapina%20e%20quetiapina%2C%20tiveram%20um%20risco%20aumentado%20de%20%20mortalidade%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Eventos%20adversos%20vascular%20cerebral%20%20Em%20estudos%20cl%26%23xED%3Bnicos%20controlados%20com%20placebo%20em%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia%2C%20tratados%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%20%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%20e%20olanzapina%2C%20houve%20%20uma%20incid%26%23xEA%3Bncia%20maior%20de%20eventos%20adversos%20vascular%20cerebral%20%20(acidente%20vascular%20cerebral%20e%20epis%26%23xF3%3Bdios%20de%20isquemia%20transit%26%23xF3%3Bria)%2C%20%20incluindo%20casos%20fatais%2C%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Doen%26%23xE7%3Ba%20de%20Parkinson%20e%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%20%20O%20m%26%23xE9%3Bdico%20deve%20pesar%20os%20riscos%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20aos%20benef%26%23xED%3Bcios%20ao%20%20prescrever%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%26%23x99%3B%2C%20para%20pacientes%20%20com%20doen%26%23xE7%3Ba%20de%20Parkinson%20ou%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%2C%20%20uma%20vez%20que%20ambos%20os%20grupos%20podem%20estar%20sob%20risco%20aumentado%20%20de%20desenvolver%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20assim%20%20como%20de%20ter%20uma%20sensibilidade%20aumentada%20a%20medicamentos%20%20antipsic%26%23xF3%3Bticos.%20A%20manifesta%26%23xE7%3B%26%23xE3%3Bo%20dessa%20sensibilidade%20aumentada%20%20pode%20incluir%20confus%26%23xE3%3Bo%2C%20embotamento%2C%20instabilidade%20postural%20%20com%20quedas%20frequentes%2C%20al%26%23xE9%3Bm%20dos%20sintomas%20extrapiramidais.%20%20Priapismo%20%20Tem%20sido%20relatado%20que%20f%26%23xE1%3Brmacos%20com%20efeitos%20de%20bloqueio%20alfaadren%26%23xE9%3Brgico%20%20induzem%20o%20priapismo.%20Embora%20nenhum%20caso%20de%20%20priapismo%20tenha%20sido%20relatado%20nos%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%20%20%26%23x99%3B%2C%20a%20paliperidona%20compartilha%20essa%20atividade%20farmacol%26%23xF3%3Bgica%20%20e%2C%20portanto%2C%20pode%20estar%20associada%20a%20esse%20risco.%20%20Controle%20da%20temperatura%20corporal%20%20A%20interrup%26%23xE7%3B%26%23xE3%3Bo%20da%20capacidade%20do%20organismo%20de%20reduzir%20a%20%20temperatura%20corporal%20foi%20atribu%26%23xED%3Bda%20a%20agentes%20antipsic%26%23xF3%3Bticos.%20%20Recomenda-se%20cuidado%20apropriado%20ao%20prescrever%20Invega%26%23x99%3B%20para%20pacientes%20que%20ir%26%23xE3%3Bo%20se%20expor%20a%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20possam%20%20contribuir%20para%20o%20aumento%20da%20temperatura%20corporal%2C%20como%20por%20%20exemplo%20exerc%26%23xED%3Bcio%20extenuante%2C%20exposi%26%23xE7%3B%26%23xE3%3Bo%20ao%20calor%20extremo%2C%20%20uso%20de%20medica%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20com%20atividade%20anticolin%26%23xE9%3Brgica%2C%20%20ou%20sujeito%20a%20desidrata%26%23xE7%3B%26%23xE3%3Bo.%20%20Efeito%20antiem%26%23xE9%3Btico%20%20Um%20efeito%20antiem%26%23xE9%3Btico%20foi%20observado%20em%20estudos%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20%20com%20a%20paliperidona.%20Esse%20efeito%2C%20se%20ocorrer%20em%20seres%20humanos%2C%20%20pode%20mascarar%20os%20sinais%20e%20sintomas%20de%20dose%20excessiva%20%20com%20certos%20f%26%23xE1%3Brmacos%20ou%20de%20condi%26%23xE7%3B%26%23xF5%3Bes%20tais%20como%20obstru%26%23xE7%3B%26%23xE3%3Bo%20%20intestinal%2C%20s%26%23xED%3Bndrome%20de%20Reye%20e%20tumor%20cerebral.%20%20Efeitos%20sobre%20a%20capacidade%20de%20dirigir%20ve%26%23xED%3Bculos%20e%20utilizar%20%20m%26%23xE1%3Bquinas%20%20Invega%26%23x99%3B%20pode%20interferir%20com%20as%20atividades%20que%20requerem%20%20alerta%20mental%20e%20pode%20ocasionar%20efeitos%20visuais%20(veja%20o%20item%20%20%26%23x93%3BRea%26%23xE7%3B%26%23xF5%3Bes%20Adversas%26%23x94%3B).%20%20Durante%20o%20tratamento%2C%20o%20paciente%20n%26%23xE3%3Bo%20deve%20dirigir%20ve%26%23xED%3Bculos%20%20ou%20operar%20m%26%23xE1%3Bquinas%2C%20pois%20sua%20habilidade%20e%20aten%26%23xE7%3B%26%23xE3%3Bo%20%20podem%20estar%20prejudicadas.%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3ERecomenda-se%20cautela%20ao%20prescrever%20Invega%20com%20medicamentos%20%20conhecidos%20por%20prolongar%20o%20intervalo%20QT.%20%20Potencial%20de%20Invega%20afetar%20outros%20f%26%23xE1%3Brmacos%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%20que%20a%20paliperidona%20cause%20intera%26%23xE7%3B%26%23xF5%3Bes%20farmacocin%26%23xE9%3Bticas%20%20clinicamente%20importantes%20com%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20P-450.%20Estudos%20%20in%20vitro%20em%20microssomas%20hep%26%23xE1%3Bticos%20humanos%20mostraram%20que%20%20a%20paliperidona%20n%26%23xE3%3Bo%20inibe%20de%20forma%20substancial%20o%20metabolismo%20%20de%20f%26%23xE1%3Brmacos%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20%20P-450%2C%20incluindo%20CYP1A2%2C%20CYP2A6%2C%20CYP2C8%2F9%2F10%2C%20CYP2D6%2C%20%20CYP2E1%2C%20CYP3A4%20e%20CYP3A5.%20Portanto%2C%20n%26%23xE3%3Bo%20se%20espera%20que%20%20a%20paliperidona%20iniba%2C%20de%20forma%20clinicamente%20relevante%2C%20a%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20metabolizados%20por%20essas%20vias%20%20metab%26%23xF3%3Blicas.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%2C%20tamb%26%23xE9%3Bm%2C%20que%20a%20paliperidona%20%20tenha%20propriedades%20indutoras%20de%20enzimas.%20%20Em%20altas%20concentra%26%23xE7%3B%26%23xF5%3Bes%2C%20a%20paliperidona%20%26%23xE9%3B%20um%20fraco%20inibidor%20da%20%20glicoprote%26%23xED%3Bna-P%20(P-gp).%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20dados%20in%20vivo%20dispon%26%23xED%3Bveis%20e%20a%20%20relev%26%23xE2%3Bncia%20cl%26%23xED%3Bnica%20%26%23xE9%3B%20desconhecida.%20%20Devido%20aos%20efeitos%20prim%26%23xE1%3Brios%20da%20paliperidona%20sobre%20o%20sistema%20%20nervoso%20central%2C%20Invega%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20outros%20f%26%23xE1%3Brmacos%20de%20a%26%23xE7%3B%26%23xE3%3Bo%20central%20e%20%26%23xE1%3Blcool.%20A%20%20paliperidona%20pode%20antagonizar%20o%20efeito%20da%20levodopa%20e%20outros%20%20agonistas%20dopamin%26%23xE9%3Brgicos.%20%20Devido%20ao%20seu%20potencial%20para%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%2C%20%20pode%20ser%20observado%20um%20efeito%20aditivo%20quando%20Invega%26%23x99%3B%20%26%23xE9%3B%20%20administrado%20com%20outros%20agentes%20terap%26%23xEA%3Buticos%20que%20possuem%20%20esse%20potencial.%20%20Potencial%20para%20outros%20f%26%23xE1%3Brmacos%20afetarem%20Invega%26%23x99%3B%20%20A%20paliperidona%20n%26%23xE3%3Bo%20%26%23xE9%3B%20um%20substrato%20da%20CYP1A2%2C%20CYP2A6%2C%20%20CYP2C9%2C%20CYP2C19%20e%20CYP3A5.%20Isso%20sugere%20que%20n%26%23xE3%3Bo%20%26%23xE9%3B%20prov%26%23xE1%3Bvel%20%20a%20ocorr%26%23xEA%3Bncia%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20com%20inibidores%20ou%20indutores%20%20dessas%20isoenzimas.%20Embora%20estudos%20in%20vitro%20indiquem%20que%20a%20%20CYP2D6%20e%20a%20CYP3A4%20podem%20estar%20minimamente%20envolvidas%20%20no%20metabolismo%20da%20paliperidona%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20indica%26%23xE7%3B%26%23xF5%3Bes%20in%20vitro%20%20nem%20in%20vivo%20de%20que%20essas%20isoenzimas%20tenham%20um%20papel%20signifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20%20P.%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona%20nifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20P.%20%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona.%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3EDados%20de%20estudos%20cl%26%23xED%3Bnicos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%201205%20pacientes%20com%20esquizofrenia%20que%20participaram%20em%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fixa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20A%20informa%26%23xE7%3B%26%23xE3%3Bo%20apresentada%20a%20seguir%20para%20os%20pacientes%20tratados%20com%20Invega%20%26%23xE9%3B%20baseada%20nos%20dados%20%20agrupados%20de%20pacientes%20que%20receberam%20Invega%20na%20dose%20di%26%23xE1%3Bria%20recomendada%20de%203%2C%206%2C%209%20ou%2012%20mg.%20Os%20termos%20para%20sistemas%20corporais%20e%20evento%20adverso%2Frea%26%23xE7%3B%26%23xE3%3Bo%20adversa%20s%26%23xE3%3Bo%20baseados%20no%20dicion%26%23xE1%3Brio%20MedDRA.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20Eventos%20adversos%20em%20estudos%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20A%20Tabela%201%20mostra%20todos%20os%20eventos%20adversos%20emergentes%20durante%20o%20tratamento%2C%20independente%20da%20causalidade%2C%20com%20incid%26%23xEA%3Bncia%20%3D1%25%20dos%20pacientes%20tratados%20com%20Invega%20nesses%20estudos%2C%20e%20para%20os%20quais%20a%20incid%26%23xEA%3Bncia%20nos%20pacientes%20tratados%20com%20Invega%20foi%20maior%20que%20nos%20pacientes%20tratados%20com%20placebo.%20%20Tabela%201%3A%20Eventos%20adversos%20emergentes%20do%20tratamento%2C%20independente%20da%20causalidade%2C%20relatados%20por%20%26gt%3B%3D%201%25%20dos%20pacientes%20com%20esquizofrenia%20em%20qualquer%20grupo%20Invega%20e%20que%20ocorreram%20em%20incid%26%23xEA%3Bncia%20maior%20que%20no%20grupo%20placebo%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20card%26%23xED%3Bacos%20%20Bloqueio%20atrioventricular%20de%201.%26%23xBA%3B%20grau%205%20(1%2C4)%202%20(1%2C6)%200%206%20(2%2C4)%202%20(0%2C8)%20%20Bradicardia%203%20(0%2C8)%200%203%20(1%2C3)%203%20(1%2C2)%204%20(1%2C7)%20%20Bloqueio%20de%20ramo%206%20(1%2C7)%204%20(3%2C1)%203%20(1%2C3)%207%20(2%2C8)%201%20(0%2C4)%20%20Palpita%26%23xE7%3B%26%23xF5%3Bes%200%202%20(1%2C6)%202%20(0%2C9)%200%203%20(1%2C2)%20%20Arritmia%20sinusal%200%203%20(2%2C4)%202%20(0%2C9)%202%20(0%2C8)%201%20(0%2C4)%20%20Taquicardia%20sinusal%2015%20(4%2C2)%2011%20(8%2C7)%209%20(3%2C8)%2010%20(4%2C1)%2017%20(7%2C0)%20%20Taquicardia%2010%20(2%2C8)%203%20(2%2C4)%2017%20(7%2C2)%2018%20(7%2C3)%2018%20(7%2C4)%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20oculares%20%20Olho%20seco%200%202%20(1%2C6)%200%201%20(0%2C4)%201%20(0%2C4)%20%20Rota%26%23xE7%3B%26%23xE3%3Bo%20ocular%200%200%200%205%20(2%2C0)%200%20%20Vis%26%23xE3%3Bo%20borrada%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%200%205%20(2%2C1)%20%20Transtornos%20gastrintestinais%20%20Dor%20abdominal%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Dor%20abdominal%20alta%202%20(0%2C6)%201%20(0%2C8)%206%20(2%2C6)%205%20(2%2C0)%204%20(1%2C7)%20%20Diarr%26%23xE9%3Bia%208%20(2%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%206%20(2%2C5)%20%20Transtornos%20gastrintestinais%20%20Boca%20seca%202%20(0%2C6)%203%20(2%2C4)%208%20(3%2C4)%202%20(0%2C8)%207%20(2%2C9)%20%20Dispepsia%2014%20(3%2C9)%203%20(2%2C4)%206%20(2%2C6)%205%20(2%2C0)%2012%20(5%2C0)%20%20N%26%23xE1%3Busea%2019%20(5%2C4)%208%20(6%2C3)%209%20(3%2C8)%2010%20(4%2C1)%2010%20(4%2C1)%20%20Hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%201%20(0%2C3)%200%201%20(0%2C4)%203%20(1%2C2)%2010%20(4%2C1)%20%20Desconforto%20estomacal%201%20(0%2C3)%202%20(1%2C6)%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Dor%20de%20dente%204%20(1%2C1)%202%20(1%2C6)%205%20(2%2C1)%206%20(2%2C4)%205%20(2%2C1)%20%20V%26%23xF4%3Bmito%2017%20(4%2C8)%202%20(1%2C6)%206%20(2%2C6)%209%20(3%2C7)%2012%20(5%2C0)%20%20Transtornos%20gerais%20%20Astenia%203%20(0%2C8)%202%20(1%2C6)%201%20(0%2C4)%205%20(2%2C0)%205%20(2%2C1)%20%20Fadiga%205%20(1%2C4)%202%20(1%2C6)%202%20(0%2C9)%204%20(1%2C6)%205%20(2%2C1)%20%20Pirexia%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%205%20(2%2C0)%204%20(1%2C7)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Bronquite%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Nasofaringite%2010%20(2%2C8)%204%20(3%2C1)%205%20(2%2C1)%204%20(1%2C6)%206%20(2%2C5)%20%20Rinite%201%20(0%2C3)%200%203%20(1%2C3)%200%201%20(0%2C4)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20vias%20a%26%23xE9%3Breas%20superiores%202%20(0%2C6)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%202%20(0%2C8)%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20viral%201%20(0%2C3)%200%201%20(0%2C4)%202%20(0%2C8)%203%20(1%2C2)%20%20Ferimento%2C%20envenenamento%20e%20%20complica%26%23xE7%3B%26%23xF5%3Bes%20de%20procedimento%20%20Queda%201%20(0%2C3)%200%203%20(1%2C3)%200%200%20%20Exames%20%20Aumento%20de%20alanina%20aminotransferase%204%20(1%2C1)%201%20(0%2C8)%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Aumento%20de%20creatina%20fosfoquinase%205%20(1%2C4)%201%20(0%2C8)%204%20(1%2C7)%200%201%20(0%2C4)%20%20Aumento%20da%20insulina%20no%20sangue%202%20(0%2C6)%203%20(2%2C4)%203%20(1%2C3)%202%20(0%2C8)%201%20(0%2C4)%20%20Aumento%20da%20press%26%23xE3%3Bo%20arterial%202%20(0%2C6)%203%20(2%2C4)%201%20(0%2C4)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20de%20triglic%26%23xE9%3Brides%20no%20sangue%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%200%200%20%20ECG%3A%20intervalo%20QT%20corrigido%20prolongado*%209%20(2%2C5)%204%20(3%2C1)%209%20(3%2C8)%207%20(2%2C8)%2012%20(5%2C0)%20%20ECG%3A%20onda%20T%20anormal%204%20(1%2C1)%203%20(2%2C4)%202%20(0%2C9)%204%20(1%2C6)%202%20(0%2C8)%20%20ECG%3A%20invers%26%23xE3%3Bo%20da%20onda%20T%203%20(0%2C8)%200%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20ECG%20anormal%200%200%200%204%20(1%2C6)%202%20(0%2C8)%20%20Aumento%20da%20frequ%26%23xEA%3Bncia%20card%26%23xED%3Baca%202%20(0%2C6)%204%20(3%2C1)%202%20(0%2C9)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20do%20pept%26%23xED%3Bdeo-C%20da%20insulina%203%20(0%2C8)%202%20(1%2C6)%203%20(1%2C3)%202%20(0%2C8)%200%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20peso%203%20(0%2C8)%202%20(1%2C6)%200%200%200%20%20Aumento%20do%20peso%205%20(1%2C4)%201%20(0%2C8)%200%204%20(1%2C6)%204%20(1%2C7)%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20apetite%200%202%20(1%2C6)%201%20(0%2C4)%201%20(0%2C4)%202%20(0%2C8)%20%20Aumento%20do%20apetite%201%20(0%2C3)%202%20(1%2C6)%200%203%20(1%2C2)%203%20(1%2C2)%20%20Transtornos%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Bticos%20%20e%20de%20tecido%20conjuntivo%20%20Artralgia%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%200%20%20Lombalgia%203%20(0%2C8)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%205%20(2%2C1)%20%20Rigidez%20muscular%200%201%20(0%2C8)%200%203%20(1%2C2)%201%20(0%2C4)%20%20Dor%20no%20pesco%26%23xE7%3Bo%201%20(0%2C3)%200%200%200%203%20(1%2C2)%20%20Dor%20em%20extremidade%204%20(1%2C1)%200%202%20(0%2C9)%200%205%20(2%2C1)%20%20Dor%20no%20ombro%200%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20do%20sistema%20nervoso%20%20Acatisia%2014%20(3%2C9)%205%20(3%2C9)%207%20(3%2C0)%2020%20(8%2C1)%2023%20(9%2C5)%20%20Vertigem%2014%20(3%2C9)%207%20(5%2C5)%2011%20(4%2C7)%2011%20(4%2C5)%2012%20(5%2C0)%20%20Discinesia%203%20(0%2C8)%200%201%20(0%2C4)%201%20(0%2C4)%204%20(1%2C7)%20%20Distonia%20%202%20(0%2C6)%2001%20(0%2C8)%203%20(1%2C3)%209%20(3%2C7)%209%20(3%2C7)%20%20Transtorno%20extrapiramidal%208%20(2%2C3)%206%20(4%2C7)%205%20(2%2C1)%2017%20(6%2C9)%2018%20(7%2C4)%20%20Cefal%26%23xE9%3Bia%2042%20(11%2C8)%2014%20(11%2C0)%2029%20(12%2C3)%2034%20(13%2C8)%2035%20(14%2C5)%20%20Hipertonia%204%20(1%2C1)%203%20(2%2C4)%203%20(1%2C3)%2010%20(4%2C1)%208%20(3%2C3)%20%20Parkinsonismo%200%200%201%20(0%2C4)%205%20(2%2C0)%203%20(1%2C2)%20%20Seda%26%23xE7%3B%26%23xE3%3Bo%2013%20(3%2C7)%201%20(0%2C8)%2012%20(5%2C1)%208%20(3%2C3)%2015%20(6%2C2)%20%20Sonol%26%23xEA%3Bncia%2012%20(3%2C4)%206%20(4%2C7)%208%20(3%2C4)%2017%20(6%2C9)%2011%20(4%2C5)%20%20S%26%23xED%3Bncope%201%20(0%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%201%20(0%2C4)%20%20Tremor%2012%20(3%2C4)%204%20(3%2C1)%206%20(2%2C6)%2011%20(4%2C5)%208%20(3%2C3)%20%20Transtornos%20psiqui%26%23xE1%3Btricos%20%20Agressividade%204%20(1%2C1)%202%20(1%2C6)%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20Ansiedade%2029%20(8%2C2)%2012%20(9%2C4)%2016%20(6%2C8)%2014%20(5%2C7)%2011%20(4%2C5)%20%20Depress%26%23xE3%3Bo%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%201%20(0%2C4)%20%20Pesadelos%200%200%201%20(0%2C4)%203%20(1%2C2)%201%20(0%2C4)%20%20Idea%26%23xE7%3B%26%23xE3%3Bo%20suicida%204%20(1%2C1)%202%20(1%2C6)%202%20(0%2C9)%201%20(0%2C4)%201%20(0%2C4)%20%20Transtornos%20respirat%26%23xF3%3Brio%2C%20tor%26%23xE1%3Bcico%20%20e%20mediast%26%23xED%3Bnico%20%20Tosse%204%20(1%2C1)%204%20(3%2C1)%204%20(1%2C7)%207%20(2%2C8)%204%20(1%2C7)%20%20Congest%26%23xE3%3Bo%20nasal%203%20(0%2C8)%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20de%20pele%20e%20de%20tecido%20subcut%26%23xE2%3Bneo%20%20Prurido%204%20(1%2C1)%200%203%20(1%2C3)%202%20(0%2C8)%200%20%20Transtornos%20vasculares%20%20Hipotens%26%23xE3%3Bo%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%202%20(0%2C8)%202%20(0%2C8)%20%20Hipotens%26%23xE3%3Bo%20ostost%26%23xE1%3Btica%203%20(0%2C8)%203%20(2%2C4)%203%20(1%2C3)%206%20(2%2C4)%209%20(3%2C7)%20%20*%20Quando%20foi%20aplicado%20um%20fator%20de%20corre%26%23xE7%3B%26%23xE3%3Bo%20apropriado%2C%20QTc%20linear%20derivado%2C%20n%26%23xE3%3Bo%20houve%20%20casos%20de%20prolongamento%20de%20QTc.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20ao%20f%26%23xE1%3Brmaco%20em%20estudos%20%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20mais%20frequentes%2C%20relatadas%20por%20%3D%202%25%20dos%20pacientes%20tratados%20%20com%20Invega%20inclu%26%23xED%3Bram%3A%20cefal%26%23xE9%3Bia%20(13%2C2%25)%2C%20taquicardia%20(6%2C6%25)%2C%20acatisia%20%20(6%2C5%25)%2C%20taquicardia%20sinusal%20(5%2C5%25)%2C%20transtorno%20extrapiramidal%20(5%2C4%25)%2C%20sonol%26%23xEA%3Bncia%20%20(4%2C9%25)%2C%20vertigem%20(4%2C8%25)%2C%20seda%26%23xE7%3B%26%23xE3%3Bo%20(4%2C2%25)%2C%20tremor%20(3%2C4%25)%2C%20hipertonia%20%20(2%2C8%25)%2C%20distonia%20(2%2C6%25)%2C%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20(2%2C5%25)%20e%20boca%20seca%20(2%2C4%25).%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20que%20parecem%20estar%20relacionadas%20%26%23xE0%3B%20dose%20foram%3A%20aumento%20%20do%20peso%2C%20cefal%26%23xE9%3Bia%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%2C%20v%26%23xF4%3Bmito%2C%20discinesia%2C%20acatisia%2C%20%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%20e%20Parkinsonismo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20descritas%20a%20seguir%20foram%20relatadas%20pelos%20pacientes%20%20com%20esquizofrenia%2C%20tratados%20com%20Invega%20(n%3D850)%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20por%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20Os%20seguintes%20termos%20e%20frequ%26%23xEA%3Bncias%20foram%20aplicados%3A%20muito%20comum%20%20(%3D10%25)%2C%20comum%20(frequente)%20(%3D1%25%20a%20%26lt%3B10%25)%2C%20incomum%20(infrequente)%20(%3D0%2C1%25%20%20a%20%26lt%3B1%25)%2C%20raro%20(%3D0%2C01%25%20a%20%26lt%3B0%2C1%25)%20e%20muito%20raro%20(%26lt%3B0%2C01%25).%20A%20maioria%20dos%20eventos%20%20adversos%20foram%20de%20gravidade%20leve%20a%20moderada.%20%20Avalia%26%23xE7%3B%26%23xF5%3Bes%3A%20comum%3A%20aumento%20de%20peso%3B%20incomum%3A%20eletrocardiograma%20%20anormal.%20%20Transtornos%20card%26%23xED%3Bacos%3A%20comum%3A%20taquicardia%20sinusal%2C%20taquicardia%20atrioventricular%2C%20%20bloqueio%20de%20primeiro%20grau%2C%20bloqueio%20de%20ramo%2C%20bradicardia%3B%20incomum%3A%20%20palpita%26%23xE7%3B%26%23xF5%3Bes%2C%20arritmia%20sinusal.%20%20Transtornos%20oculares%3A%20incomum%3A%20rota%26%23xE7%3B%26%23xE3%3Bo%20ocular.%20%20Transtornos%20gastrintestinais%3A%20comum%3A%20dor%20abdominal%20alta%2C%20boca%20seca%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20%20salivar%2C%20v%26%23xF4%3Bmito.%20%20Transtornos%20gerais%3A%20comum%3A%20astenia%2C%20fadiga%3B%20incomum%3A%20edema.%20%20Transtornos%20do%20sistema%20imunol%26%23xF3%3Bgico%3A%20incomum%3A%20rea%26%23xE7%3B%26%23xE3%3Bo%20anafi%20l%26%23xE1%3Btica.%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%3A%20incomum%3A%20aumento%20do%20apetite%20%20Transtornos%20de%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Btico%20e%20de%20tecido%20conjuntivo%3A%20incomum%3A%20%20rigidez%20muscular.%20%20Transtornos%20do%20sistema%20nervoso%3A%20muito%20comum%3A%20cefal%26%23xE9%3Bia%3B%20comum%3A%20acatisia%2C%20%20vertigem%2C%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%2C%20Parkinsonismo%2C%20%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20sonol%26%23xEA%3Bncia%2C%20tremor%3B%20incomum%3A%20vertigem%20postural%2C%20discinesia%2C%20%20convuls%26%23xE3%3Bo%20do%20tipo%20grande%20mal%2C%20s%26%23xED%3Bncope.%20%20Transtorno%20psiqui%26%23xE1%3Btrico%3A%20incomum%3A%20pesadelo.%20%20Transtorno%20do%20sistema%20reprodutor%20e%20de%20mamas%3A%20incomum%3A%20amenorr%26%23xE9%3Bia%2C%20%20secre%26%23xE7%3B%26%23xE3%3Bo%20mam%26%23xE1%3Bria%2C%20disfun%26%23xE7%3B%26%23xE3%3Bo%20er%26%23xE9%3Btil%2C%20galactorr%26%23xE9%3Bia%2C%20ginecomastia%2C%20menstrua%26%23xE7%3B%26%23xE3%3Bo%20%20irregular.%20%20Transtornos%20vasculares%3A%20comum%3A%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%3B%20incomum%3A%20hipotens%26%23xE3%3Bo%2C%20%20isquemia.%20%20Pacientes%20idosos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%2081%20pacientes%20idosos%20com%20esquizofrenia%20%20(idade%20%3D65%20anos)%20que%20receberam%20doses%20fl%20ex%26%23xED%3Bveis%20(n%3D76)%20ou%20fi%20xas%20%20(n%3D5)%20de%20Invega%20na%20faixa%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia%20por%20at%26%23xE9%3B%206%20semanas%20durante%20os%20estudos%20duplo-cegos%2C%20controlados%20com%20placebo.%20Embora%20esse%20%20conjunto%20de%20dados%20n%26%23xE3%3Bo%20permita%20uma%20compara%26%23xE7%3B%26%23xE3%3Bo%20direta%20sistem%26%23xE1%3Btica%20entre%20%20pacientes%20idosos%20e%20n%26%23xE3%3Bo%20idosos%2C%20o%20perfi%20l%20de%20seguran%26%23xE7%3Ba%20foi%20similar%20nas%20duas%20%20popula%26%23xE7%3B%26%23xF5%3Bes.%20No%20entanto%2C%20com%20base%20nesses%20dados%20limitados%20e%20consistente%20%20com%20a%20pr%26%23xE1%3Btica%20cl%26%23xED%3Bnica%20geral%2C%20n%26%23xE3%3Bo%20%26%23xE9%3B%20poss%26%23xED%3Bvel%20excluir%20uma%20maior%20sensibilidade%20%20de%20indiv%26%23xED%3Bduos%20mais%20idosos%20a%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas.%20%20Eventos%20de%20interesse%20particular%20para%20a%20classe%20%20Sintomas%20extrapiramidais%3A%20os%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20revelaram%20%20diferen%26%23xE7%3Bas%20nos%20eventos%20extrapiramidais%20que%20surgiram%20com%20o%20tratamento%2C%20%20comparando-se%20o%20placebo%20(11%25)%20e%20Invega%203%20e%206%20mg%20(13%25%20e%2010%25%2C%20%20respectivamente).%20Sintomas%20extrapiramidais%20relacionados%20%26%23xE0%3B%20dose%20foram%20%20observados%20nas%20duas%20dosagens%20maiores%20de%20Invega%20(25%25%20e%2026%25%20para%20%20as%20doses%20de%209%20e%2012%20mg%2C%20respectivamente).%20Os%20sintomas%20extrapiramidais%20%20inclu%26%23xED%3Bram%20uma%20an%26%23xE1%3Blise%20agrupada%20dos%20seguintes%20termos%3A%20discinesia%2C%20distonia%2C%20%20hipercinesia%2C%20Parkinsonismo%20e%20tremor.%20%20Ganho%20de%20peso%3A%20nos%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20as%20propor%26%23xE7%3B%26%23xF5%3Bes%20de%20%20pacientes%20que%20atingiram%20o%20crit%26%23xE9%3Brio%20de%20ganho%20de%20peso%20%3D7%25%20do%20peso%20corporal%20%20foram%20comparadas%20e%20revelaram%20uma%20incid%26%23xEA%3Bncia%20similar%20de%20ganho%20de%20peso%20%20para%20Invega%203%20mg%20(7%25)%20e%206%20mg%20(6%25)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo%20(5%25)%20e%20%20uma%20maior%20incid%26%23xEA%3Bncia%20de%20ganho%20de%20peso%20para%209%20mg%20(9%25)%20e%2012%20mg%20(9%25).%20%20Exames%20laboratoriais%3A%20Prolactina%20s%26%23xE9%3Brica%3A%20com%20base%20nos%20dados%20agrupados%20%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20foram%20observados%20aumentos%20medianos%20na%20prolactina%20%20s%26%23xE9%3Brica%20em%20pacientes%20de%20ambos%20os%20sexos%20que%20receberam%20Invega.%20Os%20%20aumentos%20m%26%23xE9%3Bdios%20m%26%23xE1%3Bximos%20da%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20prolactina%20s%26%23xE9%3Brica%20foram%20%20observados%2C%20em%20geral%2C%20no%2015%26%23xBA%3B%20dia%20do%20tratamento%2C%20mas%20permaneceram%20acima%20%20dos%20n%26%23xED%3Bveis%20da%20linha%20de%20base%20ao%20fi%20nal%20do%20estudo.%20%20Estudos%20Cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20em%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20%20controlado%20por%20placebo%3A%20a%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20tamb%26%23xE9%3Bm%20avaliada%20em%20%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20delineado%20para%20avaliar%20manuten%26%23xE7%3B%26%23xE3%3Bo%20do%20efeito%20de%20%20Invega%20em%20adultos%20com%20esquizofrenia.%20Em%20geral%2C%20os%20tipos%2C%20freq%26%23xFC%3B%26%23xEA%3Bncias%20e%20%20gravidades%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%2C%20relatados%20durante%20a%20fase%20inicial%2C%20%20aberta%2C%20de%2014%20semanas%20deste%20estudo%2C%20foram%20compar%26%23xE1%3Bveis%20%26%23xE0%3B%20aqueles%20relatados%20%20no%20estudo%20de%20curto%20prazo%2C%20por%2006%20semanas%2C%20com%20dose-fi%20xa%2C%20controlado%20%20por%20placebo.%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20relatadas%20durante%20a%20fase%20de%20%20longo%20prazo%2C%20duplo-cega%20deste%20estudo%20foram%20similares%20em%20tipo%20e%20gravidade%20%20%26%23xE0%3Bs%20observadas%20na%20fase%20aberta%2C%20inicial%2C%20com%20dura%26%23xE7%3B%26%23xE3%3Bo%20de%2014%20semanas%3B%20entretanto%2C%20%20em%20geral%20ocorreram%20em%20freq%26%23xFC%3B%26%23xEA%3Bncias%20menores.%20%20Informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20relacionados%20%26%23xE0%3B%20risperidona%3A%20a%20paliperidona%20corresponde%20%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%20O%20perfi%20l%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20da%20%20droga%20e%20as%20propriedades%20farmacocin%26%23xE9%3Bticas%20de%20Invega%20s%26%23xE3%3Bo%20consideralvemente%20%20diferentes%20das%20observadas%20com%20formula%26%23xE7%3B%26%23xF5%3Bes%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20imediata%2C%20para%20admnistra%26%23xE7%3B%26%23xE3%3Bo%20via%20oral%2C%20contendo%20risperidona.%20As%20informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20%20relatadas%20com%20risperidona%20em%20estudos%20cl%26%23xED%3Bnicos%20e%20em%20experi%26%23xEA%3Bncia%20%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20que%20n%26%23xE3%3Bo%20foram%20relatadas%20com%20Invega%20podem%20ser%20%20encontradas%20na%20bula%20de%20medicamentos%20contendo%20risperidona.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3EINVEGA%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EAdultos%20(idade%20acima%20de%2018%20anos)%20%20A%20dose%20de%20Invega%20recomendada%20%26%23xE9%3B%20de%206%20mg%20uma%20vez%20ao%20dia%2C%20por%20via%20oral%2C%20%20administrado%20pela%20manh%26%23xE3%3B%20com%20ou%20sem%20alimentos.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20titular%20%20a%20dose%20inicial.%20Alguns%20pacientes%20podem%20se%20benefi%20ciar%20de%20doses%20mais%20altas%20%20ou%20mais%20baixas%20dentro%20da%20faixa%20recomendada%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia.%20%20Se%20indicados%2C%20os%20ajustes%20da%20dose%20podem%20ser%20feitos%20ap%26%23xF3%3Bs%20reavalia%26%23xE7%3B%26%23xE3%3Bo%20cl%26%23xED%3Bnica.%20%20Quando%20aumentos%20de%20dose%20s%26%23xE3%3Bo%20indicados%2C%20recomenda-se%20aumentos%20de%203%20%20mg%2Fdia%20e%20devem%20geralmente%20ocorrer%20em%20intervalos%20maiores%20do%20que%205%20dias.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20leve%20%26%23xE0%3B%20moderada.%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20%20hep%26%23xE1%3Btica%20grave.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20leve%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20creatinina%20%3D50%20a%20%20%26lt%3B%2080%20mL%2Fmin)%2C%20a%20dose%20inicial%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20dia.%20A%20dose%20%20pode%20ser%20aumentada%20para%206%20mg%20uma%20vez%20ao%20dia%20baseados%20na%20tolerabilidade%20%20e%20resposta%20cl%26%23xED%3Bnica.%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20moderada%20a%20grave%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20%20creatinina%20%3D10%20a%20%26lt%3B%2050%20mL%2Fmin)%2C%20a%20dose%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20%20dia.%20Como%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20depura%26%23xE7%3B%26%23xE3%3Bo%20de%20%20creatinina%20%26lt%3B%2010%20mL%2Fmin%20%2C%20n%26%23xE3%3Bo%20se%20recomenda%20o%20uso%20nestes%20pacientes.%20%20Pacientes%20idosos%20%20As%20recomenda%26%23xE7%3B%26%23xF5%3Bes%20posol%26%23xF3%3Bgicas%20para%20pacientes%20idosos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal%20(%3D%2080%20mL%2Fmin)%20s%26%23xE3%3Bo%20as%20mesmas%20que%20as%20para%20adultos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal.%20No%20entanto%2C%20como%20os%20pacientes%20idosos%20podem%20ter%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20diminu%26%23xED%3Bda%2C%20pode%20ser%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20de%20acordo%20com%20o%20estado%20da%20%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20%20Crian%26%23xE7%3Bas%20%20A%20seguran%26%23xE7%3Ba%20e%20a%20efi%20c%26%23xE1%3Bcia%20de%20Invega%20n%26%23xE3%3Bo%20foram%20avaliadas%20em%20pacientes%20%20com%20idade%20inferior%20a%2018%20anos.%20%20Outras%20popula%26%23xE7%3B%26%23xF5%3Bes%20especiais%20%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20recomenda%26%23xE7%3B%26%23xE3%3Bo%20para%20ajuste%20da%20dose%20de%20Invega%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20do%20%20sexo%2C%20ra%26%23xE7%3Ba%20ou%20tabagismo.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3ESintomas%20%20Em%20geral%2C%20os%20sinais%20e%20sintomas%20esperados%20s%26%23xE3%3Bo%20aqueles%20resultantes%20de%20uma%20%20exacerba%26%23xE7%3B%26%23xE3%3Bo%20dos%20efeitos%20farmacol%26%23xF3%3Bgicos%20conhecidos%20da%20paliperidona%2C%20isto%20%20%26%23xE9%3B%2C%20sonol%26%23xEA%3Bncia%20e%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20taquicardia%20e%20hipotens%26%23xE3%3Bo%2C%20prolongamento%20QT%20e%20%20sintomas%20extrapiramidais.%20No%20caso%20de%20superdose%20aguda%2C%20a%20possibilidade%20%20de%20envolvimento%20de%20v%26%23xE1%3Brios%20f%26%23xE1%3Brmacos%20deve%20ser%20considerada.%20%20Tratamento%20%20Ao%20avaliar%20a%20necessidade%20de%20tratamento%20e%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20deve-se%20considerar%20%20a%20natureza%20da%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20do%20medicamento.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20ant%26%23xED%3Bdoto%20%20espec%26%23xED%3Bfi%20co%20para%20a%20paliperidona.%20Medidas%20gerais%20de%20suporte%20devem%20%20ser%20adotadas.%20Estabelecer%20e%20manter%20as%20vias%20a%26%23xE9%3Breas%20e%20garantir%20oxigena%26%23xE7%3B%26%23xE3%3Bo%20%20e%20ventila%26%23xE7%3B%26%23xE3%3Bo%20adequadas.%20O%20monitoramento%20cardiovascular%20deve%20ser%20iniciado%20%20imediatamente%20e%20deve%20incluir%20monitoramento%20eletrocardiogr%26%23xE1%3Bfico%20cont%26%23xED%3Bnuo%20para%20poss%26%23xED%3Bveis%20arritmias.%20Hipotens%26%23xE3%3Bo%20e%20colapso%20circulat%26%23xF3%3Brio%20devem%20%20ser%20tratados%20com%20medidas%20apropriadas%20tais%20como%20l%26%23xED%3Bquidos%20intravenosos%20e%2F%20%20ou%20agentes%20simpatomim%26%23xE9%3Bticos.%20A%20lavagem%20g%26%23xE1%3Bstrica%20(ap%26%23xF3%3Bs%20intuba%26%23xE7%3B%26%23xE3%3Bo%20se%20o%20%20paciente%20estiver%20inconsciente)%20e%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20carv%26%23xE3%3Bo%20ativado%20junto%20%20com%20um%20laxativo%20devem%20ser%20consideradas.%20Na%20presen%26%23xE7%3Ba%20de%20sintomas%20extrapiramidais%20%20graves%2C%20agentes%20anticolin%26%23xE9%3Brgicos%20devem%20ser%20administrados.%20%20Uma%20supervis%26%23xE3%3Bo%20cuidadosa%20e%20o%20monitoramento%20devem%20continuar%20at%26%23xE9%3B%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20do%20paciente.%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EINVEGA%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%09%09%09%09%09%09
Ame
Sim
ApresentarPrecoDePor
Sim
custom_label_0
campanha
MedicamentoControlado
Sim
Cashback
Não
Antibiotico
Não
Generico
Não

Tributos e contexto fiscal

Escolha o estado para ver os tributos deste produto:
Preferência salva neste navegador; confirme o destino da operação.

NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.

Selecione a UF nesta seção para consultar a estimativa IBPT.

IBS/CBS: o cClassTrib acima vem do enquadramento do NCM; percentuais dependem da operação, regime, data e destino.

Medicamento — dados oficiais

Medicamento
INVEGA 100 MG/ML SUS INJ LIB PROL IM CT 1 SER PREENC PLAS COC TRANS X 0,50 ML+ 2 AGU
Princípio ativo
PALMITATO DE PALIPERIDONA
Laboratório
JANSSEN-CILAG FARMACEUTICA LTDA
Registro ANVISA
1123633980049
Classe terapêutica
N5A1 - ANTIPSICÓTICOS ATÍPICOS
Tipo
Novo
Tarja
Tarja Vermelha
PIS/COFINS
Lista negativa (PIS/COFINS monofásico, sem crédito presumido)

Fonte: CMED/ANVISA, lista de preços de medicamentos publicada em 09/10/2026. Confirme a tributação com seu contador.

INVEGA SUSTENNA 50 MG ML SERINGA PREENCHIDA 0 5 ML SIMILAR - Invega

Dados estruturados

Veja como a API devolve os dados de um produto.

Exemplo ilustrativo, igual em todas as páginas. Os dados reais deste código de barras vêm da API, com o seu token.

GET https://global.si5.com.br/index.php/api/produtos/123456788


            

Para chamar a API de verdade você usa um token pessoal — grátis até 30 consultas por dia.

Histórico de preços

Como o preço deste produto variou.

Preços de referência coletados em lojas online. Uma nova coleta acontece a cada cerca de 30 dias e sempre que o preço muda.

Último preçoR$ 1.760,58
Variação no período+13,6%
Menor / maiorR$ 1.549,99 / R$ 1.800,99
Coletas3
1.549,99 1.633,66 1.717,32 1.800,99 03/10/2026: R$ 1.549,99 (paguemenos.com.br) 11/10/2026: R$ 1.800,99 (araujo.vtexcommercestable.com.br) 15/10/2026: R$ 1.760,58 (pill.com.br) 1.549,99 1.760,58 03/10 15/10
DataPreçoVariaçãoFonte
15/10/2026 R$ 1.760,58 primeira coleta pill.com.br
11/10/2026 R$ 1.800,99 primeira coleta araujo.vtexcommercestable.com.br
03/10/2026 R$ 1.549,99 primeira coleta paguemenos.com.br

Valores informativos coletados de lojas online, sem garantia de que estejam atualizados. Não representam preço de venda do SI5 Global.